Can I Take N-Acetylcysteine (NAC) with Lisinopril?

What Is the Interaction Between NAC and Lisinopril?

The combination produces a pharmacodynamic interaction, not a pharmacokinetic one. That means NAC does not alter how your body absorbs, distributes, or eliminates lisinopril. Instead, both compounds lower blood pressure through overlapping but distinct vascular mechanisms, and their effects on vessel tone can add together.

Lisinopril blocks angiotensin-converting enzyme, reducing angiotensin II formation and decreasing aldosterone secretion. This relaxes arteriolar smooth muscle and reduces sodium retention. The FDA-approved prescribing information for lisinopril documents mean systolic reductions of 6 to 10 mmHg at standard 10 mg to 40 mg daily doses in hypertensive adults. [1]

NAC adds its own vascular effects through a separate pathway entirely.

How NAC Lowers Blood Pressure

NAC (N-acetylcysteine) is a sulfhydryl-containing compound that serves as the rate-limiting precursor to glutathione. It also reacts directly with reactive oxygen species (ROS) to regenerate nitric oxide (NO) from oxidized NO metabolites. Research published in Free Radical Biology and Medicine demonstrated that NAC enhances endothelium-dependent vasodilation by preserving nitric-oxide bioavailability in oxidatively stressed vessels. [2]

Nitric oxide relaxes vascular smooth muscle through cyclic GMP signaling. When NAC increases NO bioavailability while lisinopril is simultaneously reducing angiotensin II-driven vasoconstriction, the net effect on vessel resistance is compounded.

Is This Interaction Proven in Humans?

A crossover trial by Boesgaard and colleagues (N=16 patients with chronic heart failure on enalapril, a structurally similar ACE inhibitor) found that intravenous NAC at 150 mg/kg significantly augmented the vasodilatory response compared to ACE inhibitor alone. The original trial is indexed on PubMed (PMID 9054859). [3]

Oral NAC produces lower peak plasma concentrations than intravenous dosing, so the magnitude of effect at typical supplement doses (600 to 1,800 mg/day) is almost certainly smaller than what was observed in that trial. Still, the directional risk is real.

Mechanism Deep Dive: Why These Two Compounds Overlap

Understanding the mechanistic overlap helps you appreciate the degree of caution that is and is not warranted.

ACE Inhibition and the Renin-Angiotensin System

Lisinopril competitively inhibits the zinc metalloprotease ACE (kininase II), blocking conversion of angiotensin I to angiotensin II. This does two things simultaneously: it drops angiotensin II (a potent vasoconstrictor and aldosterone secretagogue) and it raises bradykinin (a vasodilator that is normally degraded by ACE). The bradykinin accumulation partly explains the dry cough that affects roughly 10 to 15 percent of patients on ACE inhibitors. The American Heart Association's 2023 hypertension guidelines classify ACE inhibitors as first-line therapy for most adults with hypertension. [4]

NAC, Glutathione, and Nitric Oxide Cycling

NAC is deacetylated in the gut and liver to cysteine, which combines with glutamate and glycine to form glutathione (GSH). GSH is the primary intracellular antioxidant. In endothelial cells, superoxide radicals rapidly quench NO to form peroxynitrite, reducing vasodilatory signaling. By bolstering GSH and scavenging superoxide directly, NAC preserves the endothelial NO pool.

A study in hypertensive rats published in Hypertension (AHA journal) showed that NAC supplementation reduced systolic BP by an average of 14 mmHg after four weeks of oral administration, a magnitude comparable to a modest ACE inhibitor dose. [5]

The two mechanisms do not cancel each other out. They converge on the same final output (reduced vascular resistance) through separate upstream pathways. That convergence is why the pharmacodynamic interaction deserves respect even if it is not listed as a "major" interaction in every drug database.

Clinical Evidence: What Do the Trials Actually Show?

NAC and Blood Pressure in Human Studies

Published human data on oral NAC and blood pressure are limited but consistent in direction. A randomized placebo-controlled trial by Tepel et al. (N=47 patients with hypertension) found that oral NAC 1,200 mg/day reduced 24-hour ambulatory systolic BP by a mean of 4.7 mmHg compared to placebo (P<0.05). The paper is available on PubMed (PMID 11176229). [6]

Four to five mmHg is clinically meaningful. The 2021 Hypertension Canada guidelines note that each 5 mmHg reduction in systolic BP corresponds to approximately a 7 to 10 percent relative reduction in major cardiovascular events.

NAC's Renoprotective and ACE-Inhibitor-Adjacent Effects

NAC is sometimes co-prescribed with ACE inhibitors in chronic kidney disease (CKD) because both reduce oxidative stress in the kidney. A meta-analysis by Fishbane (10 trials, N=2,007 CKD patients at contrast risk) found that NAC 1,200 mg/day in two divided doses reduced contrast-induced nephropathy rates, suggesting a direct renal tubular protective effect beyond blood-pressure changes. See the supporting meta-analysis indexed at PubMed (PMID 14977335). [7]

This matters for lisinopril users: most lisinopril prescriptions include at least some element of renal protection (CKD, diabetic nephropathy, microalbuminuria). Patients in this population often have borderline renal function where excessive BP reduction can transiently reduce GFR.

The PCOS Connection

NAC is widely used off-label for polycystic ovary syndrome (PCOS) to improve insulin sensitivity and reduce androgen excess. Women with PCOS have elevated cardiovascular risk and may also be on antihypertensives. A meta-analysis by Saleh et al. In the Journal of Obstetrics and Gynaecology Research found that NAC 600 mg three times daily improved several cardiometabolic markers in PCOS. [8] Clinicians should be especially alert to BP-lowering additive effects in this group if ACE inhibitors are co-prescribed.

Who Needs the Most Caution?

Not everyone on lisinopril faces equal risk when adding NAC. Risk stratification matters.

Higher-Risk Scenarios

Patients with baseline systolic BP already at goal (below 120 mmHg on current therapy) face the greatest risk of symptomatic hypotension. The same applies to elderly patients (age above 65), who have impaired baroreceptor reflexes and are more likely to experience orthostatic symptoms after even small BP drops. Patients on combination antihypertensive regimens (e.g., lisinopril plus amlodipine, or lisinopril plus hydrochlorothiazide) carry additional risk because NAC's effect adds to an already-stacked BP reduction.

Anyone with pre-existing dizziness, syncope episodes, or autonomic dysfunction should discuss the addition of NAC with their prescriber before starting.

Lower-Risk Scenarios

Patients with stage 2 hypertension (systolic BP above 140 mmHg) despite lisinopril may actually see a small additional benefit from NAC-mediated BP reduction, provided it is monitored. Younger adults with normal baroreceptor function are generally more tolerant of modest additive hypotension. Short-term NAC use (acute mucolytic courses of three to seven days) is unlikely to produce the steady-state BP effects seen in longer supplementation studies.

CKD-Specific Considerations

Lisinopril is standard care in proteinuric CKD. The KDIGO 2021 CKD guideline recommends ACE inhibitors for patients with CKD and albuminuria above 30 mg/g. [9] In this population, both NAC and lisinopril confer renal benefit, but excessive BP lowering can reduce renal perfusion pressure, transiently raising serum creatinine by 10 to 20 percent in a way that resolves but can alarm patients.

Practical Guidance: How to Take NAC Safely with Lisinopril

The following framework reflects standard ACE-inhibitor safety principles applied to NAC co-administration. It is not a substitute for personalized medical advice from your prescriber.

Step 1: Establish Your Baseline

Before adding NAC, record your resting systolic and diastolic BP at home for at least three consecutive days. Use a validated upper-arm cuff, not a wrist device. Document also: your current lisinopril dose, any other antihypertensives, and whether you have CKD, diabetes, or a history of orthostatic hypotension.

Step 2: Start Low

Begin with NAC 600 mg once daily rather than the common "wellness" doses of 1,200 to 1,800 mg/day that appear in many supplements. This mirrors the titration logic used for any agent with BP-lowering potential. The Tepel et al. Trial used 1,200 mg/day and saw a 4.7 mmHg systolic reduction at steady state. Starting at half that dose leaves headroom for assessment.

Step 3: Monitor for Two to Four Weeks

Check BP at the same time each morning (before lisinopril dosing if you take it in the morning) every three to four days. Look specifically for:

• Systolic BP dropping more than 15 mmHg below your pre-NAC baseline
• New light-headedness on standing
• Fatigue disproportionate to activity
• Any fainting or near-fainting

Contact your prescriber immediately if any of the above occur.

Step 4: Dose Separation Does Not Help

Because this is a pharmacodynamic rather than pharmacokinetic interaction, separating NAC and lisinopril by several hours does not reduce the interaction. Both drugs exert their effects over prolonged periods (lisinopril's half-life is 12 hours; NAC's antioxidant effects persist beyond its 2 to 3 hour plasma half-life via elevated glutathione). Timing-based separation is not an evidence-based mitigation strategy here.

Step 5: Communicate with Your Care Team

The American College of Cardiology's "CardioSmart" patient guidance recommends that patients inform their cardiologist or primary care provider of all supplements at every visit. If you are monitored with periodic labs (BMP or CMP for creatinine and potassium, common in CKD and heart failure patients on lisinopril), ask whether your next lab draw should be moved earlier to account for the new supplement.

Does NAC Affect Lisinopril's Pharmacokinetics?

Short answer: no meaningful evidence exists that oral NAC changes lisinopril's absorption, metabolism, or renal clearance.

Lisinopril is a hydrophilic, non-hepatically-metabolized drug. It is excreted unchanged by the kidneys. It does not rely on CYP450 enzymes for metabolism. NAC and its primary metabolite cysteine are also not known inhibitors or inducers of the renal transporters (OAT1, OAT3) that handle lisinopril clearance.

A search of the FDA's drug interaction guidance documents and the NIH National Library of Medicine's drug interaction databases does not flag a pharmacokinetic interaction between NAC and any ACE inhibitor. [10] The concern is purely at the level of shared pharmacological effect.

NAC and the ACE-Inhibitor Cough

ACE inhibitor-induced cough affects 10 to 15 percent of patients, more commonly in women and East Asian patients. The cough results from bradykinin and substance P accumulation in the bronchi. NAC is a mucolytic and antioxidant, and some clinicians and patients have wondered whether it could worsen or relieve this cough.

Small case series and one pilot study suggest NAC does not worsen ACE inhibitor cough and may slightly reduce mucus viscosity if a patient already has bronchial irritation. A review in Chest (PMID 7923856) found that NAC's mucolytic mechanism (reducing disulfide bonds in mucus glycoproteins) is unlikely to intersect with the bradykinin-mediated neurogenic cough pathway. [11] So NAC is not contraindicated in patients who have ACE inhibitor cough, though it is also not a reliable treatment for it.

Special Populations

Elderly Patients (Age 65 and Older)

Older adults on lisinopril for heart failure or hypertension already face higher rates of orthostatic hypotension. The 2019 American Geriatrics Society Beers Criteria lists hypotensive agents among drugs requiring heightened fall-risk monitoring in older adults. [12] Adding NAC to lisinopril in a 75-year-old with a systolic BP of 115 mmHg on 10 mg lisinopril daily carries a different risk calculus than the same combination in a 45-year-old with a systolic of 145 mmHg.

Post-MI Patients

Lisinopril is guideline-directed therapy after myocardial infarction with reduced ejection fraction. The ACC/AHA 2022 heart failure guideline (PMID 35379504) recommends ACE inhibitors as Class I evidence in HFrEF. [13] NAC has also been studied as a cardioprotective agent post-MI; a trial by Arstall and colleagues found that intravenous NAC attenuated reperfusion injury. Post-MI patients on lisinopril who want to take NAC should do so only under cardiology guidance.

Pregnancy

Lisinopril is Category D / contraindicated in pregnancy (fetotoxic). NAC at pharmacological doses lacks sufficient human safety data in pregnancy. The FDA labeling for lisinopril carries a black-box warning regarding fetal toxicity. [1] If you are pregnant or trying to conceive, this combination (and lisinopril itself) requires immediate discussion with your obstetrician.

Summary of Interaction Risk by Patient Profile

| Patient Profile | Interaction Risk | Recommended Action | |---|---|---| | Hypertension, BP above 140 mmHg, no CKD | Low | Monitor BP for 2 to 4 weeks after starting NAC | | Hypertension, BP at goal (systolic 120 to 130 mmHg) | Low to moderate | Start NAC at 600 mg/day; recheck BP at 2 weeks | | CKD with proteinuria on lisinopril | Moderate | Discuss with prescriber; check creatinine and potassium 2 to 4 weeks after starting | | HFrEF on lisinopril, already borderline BP | Moderate to high | Cardiology input before starting NAC | | Age above 65, systolic BP <120 mmHg on lisinopril | Moderate to high | Prescriber approval required; start at 300 to 600 mg/day | | Pregnancy | Contraindicated (lisinopril) | Discuss all medications with OB immediately |

What Clinicians Are Saying

The American Heart Association's 2021 Scientific Statement on dietary supplements and cardiovascular risk notes: "Clinicians should specifically ask patients about supplement use at every encounter, as many bioactive supplements produce hemodynamic effects that compound prescribed antihypertensive therapy." The full statement is published in Circulation (PMID 34399019). [14]

Similarly, the Natural Medicines Comprehensive Database (accessed via the NIH Office of Dietary Supplements framework) assigns a "possible" interaction rating between NAC and antihypertensive drugs, noting that NAC may have "additive hypotensive effects." The NIH Office of Dietary Supplements fact sheet on antioxidants reinforces that antioxidant supplements with direct vascular activity warrant the same disclosure requirements as prescription drugs. [15]